200 related articles for article (PubMed ID: 18829495)
1. Therapeutic IMC-C225 antibody inhibits breast cancer cell invasiveness via Vav2-dependent activation of RhoA GTPase.
Molli PR; Adam L; Kumar R
Clin Cancer Res; 2008 Oct; 14(19):6161-70. PubMed ID: 18829495
[TBL] [Abstract][Full Text] [Related]
2. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
3. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS; Hong WK
Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
Karashima T; Sweeney P; Slaton JW; Kim SJ; Kedar D; Izawa JI; Fan Z; Pettaway C; Hicklin DJ; Shuin T; Dinney CP
Clin Cancer Res; 2002 May; 8(5):1253-64. PubMed ID: 12006546
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
Herbst RS; Langer CJ
Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice.
Overholser JP; Prewett MC; Hooper AT; Waksal HW; Hicklin DJ
Cancer; 2000 Jul; 89(1):74-82. PubMed ID: 10897003
[TBL] [Abstract][Full Text] [Related]
7. Mechanical stretch-induced RhoA activation is mediated by the RhoGEF Vav2 in mesangial cells.
Peng F; Zhang B; Ingram AJ; Gao B; Zhang Y; Krepinsky JC
Cell Signal; 2010 Jan; 22(1):34-40. PubMed ID: 19755152
[TBL] [Abstract][Full Text] [Related]
8. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.
Buchsbaum DJ; Bonner JA; Grizzle WE; Stackhouse MA; Carpenter M; Hicklin DJ; Bohlen P; Raisch KP
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1180-93. PubMed ID: 12419447
[TBL] [Abstract][Full Text] [Related]
9. [EGFR-blockade by antibody Cetuximab inhibits the growth of human gastric cancer xenograft in nude mice and its possible mechanism].
Zhang J; Ji J; Yuan F; Ma T; Ye ZB; Yu YY; Liu BY; Zhu ZG
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):85-9. PubMed ID: 19538880
[TBL] [Abstract][Full Text] [Related]
10. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.
Herbst RS; Kim ES; Harari PM
Expert Opin Biol Ther; 2001 Jul; 1(4):719-32. PubMed ID: 11727507
[TBL] [Abstract][Full Text] [Related]
11. VAV2 regulates epidermal growth factor receptor endocytosis and degradation.
Thalappilly S; Soubeyran P; Iovanna JL; Dusetti NJ
Oncogene; 2010 Apr; 29(17):2528-39. PubMed ID: 20140013
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
[TBL] [Abstract][Full Text] [Related]
13. Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFR/Vav2 signaling axis involved in cell invasion.
Patel V; Rosenfeldt HM; Lyons R; Servitja JM; Bustelo XR; Siroff M; Gutkind JS
Carcinogenesis; 2007 Jun; 28(6):1145-52. PubMed ID: 17234718
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
16. Fer protein-tyrosine kinase promotes lung adenocarcinoma cell invasion and tumor metastasis.
Ahn J; Truesdell P; Meens J; Kadish C; Yang X; Boag AH; Craig AW
Mol Cancer Res; 2013 Aug; 11(8):952-63. PubMed ID: 23699534
[TBL] [Abstract][Full Text] [Related]
17. Effect of cetuximab and fractionated irradiation on tumour micro-environment.
Santiago A; Eicheler W; Bussink J; Rijken P; Yaromina A; Beuthien-Baumann B; van der Kogel AJ; Baumann M; Krause M
Radiother Oncol; 2010 Nov; 97(2):322-9. PubMed ID: 20667608
[TBL] [Abstract][Full Text] [Related]
18. Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications.
Ciardiello F; Tortora G
Clin Cancer Res; 1998 Apr; 4(4):821-8. PubMed ID: 9563874
[TBL] [Abstract][Full Text] [Related]
19. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
20. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.
Saleh MN; Raisch KP; Stackhouse MA; Grizzle WE; Bonner JA; Mayo MS; Kim HG; Meredith RF; Wheeler RH; Buchsbaum DJ
Cancer Biother Radiopharm; 1999 Dec; 14(6):451-63. PubMed ID: 10850332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]